In addition to hepassocin's role in the development of NAFLD, the hepassocin promoter is transcriptionally upregulated through an IL-6/IL-6R/STAT3 signaling pathway, which maintains metabolic homeostasis 33. This evidence concerns the gene IL6R and metabolic dysfunction-associated steatotic liver disease.